HC Wainwright Forecasts Weaker Earnings for SOPHiA GENETICS

Key Points

• HC Wainwright cut its FY2026 EPS forecast for SOPHiA GENETICS to a loss of $0.94 per share from a projected loss of $0.77, while keeping its Buy rating and $14 price target.
• The company reported a quarterly loss of $0.24 per share, missing the $0.20 loss analysts expected, although revenue of $24.27 million topped estimates of $24.03 million.
• Analyst sentiment overall is mixed: MarketBeat reports a consensus Hold rating and a $10 price target, with three Buy ratings, one Hold, and one Sell.

SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) - Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of SOPHiA GENETICS in a research note issued to investors on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.94) for the year, down from their previous forecast of ($0.77). HC Wainwright currently has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for SOPHiA GENETICS's current full-year earnings is ($0.77) per share. HC Wainwright also issued estimates for SOPHiA GENETICS's Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.49) EPS.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.04). The company had revenue of $24.27 million during the quarter, compared to analyst estimates of $24.03 million. SOPHiA GENETICS had a negative return on equity of 128.69% and a negative net margin of 89.18%.

SOPH has been the topic of a number of other reports. BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Trading Down 5.0%

Shares of SOPHiA GENETICS stock opened at $6.62 on Friday. The firm's 50 day simple moving average is $7.74 and its two-hundred day simple moving average is $5.98. The firm has a market capitalization of $555.38 million, a price-to-earnings ratio of -6.07 and a beta of 1.09. SOPHiA GENETICS has a 12-month low of $3.83 and a 12-month high of $8.98. The company has a current ratio of 2.29, a quick ratio of 2.55 and a debt-to-equity ratio of 0.70.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $9,809,000. Principal Financial Group Inc. increased its holdings in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS during the 1st quarter valued at approximately $1,772,000. Sowell Financial Services LLC acquired a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $2,865,000. Finally, Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter valued at $866,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Insider Activity at SOPHiA GENETICS

In other SOPHiA GENETICS news, insider Philippe Menu sold 7,394 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $60,113.22. Following the sale, the insider directly owned 200,993 shares of the company's stock, valued at approximately $1,634,073.09. This trade represents a 3.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathy L. Hibbs sold 6,250 shares of SOPHiA GENETICS stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $8.13, for a total value of $50,812.50. Following the transaction, the director owned 96,992 shares of the company's stock, valued at $788,544.96. The trade was a 6.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 170,662 shares of company stock valued at $1,372,619 over the last ninety days. Corporate insiders own 4.88% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company's primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.